Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study
|Published in||Antiviral Therapy. 2010, vol. 15, no. 3, p. 413-423|
|Abstract||BACKGROUND: Potential drug-drug interactions (PDDIs) might expand with new combination antiretroviral therapies (ART) and polypharmacy related to increasing age and comorbidities. We investigated the prevalence of comedications and PDDIs within a large HIV cohort, and their effect on ART efficacy and tolerability. METHODS: All medications were prospectively recorded in 1,497 ART-treated patients and screened for PDDIs using a customized version of the Liverpool drug interactions database. RESULTS: Overall, 68% (1,013/1,497) of patients had a comedication and 40% (599/1,497) had ≥ 1 PDDI. Among patients with comedication, 2% (21/1,013) had red-flag interactions (contraindicated) and 59% (597/1,013) had orange-flag interactions (potential dose adjustment and/or close monitoring required). The latter involved mainly central nervous system drugs (49%), cardiovascular drugs (34%) and methadone (19%). In the multivariate analysis, factors associated with having a comedication were advanced age, female gender, obesity and HCV infection. Independent risk factors for PDDIs were regimens combining protease inhibitors and non-nucleoside reverse transcriptase inhibitors (odds ratio [OR] 3.06, 95% confidence interval [CI] 1.44-6.48), ≥ 2 comedications (OR 1.89, 95% CI 1.32-2.70), current illicit drug use (OR 2.00, 95% CI 1.29-3.10) and patients with HCV infection (OR 1.74, 95% CI 1.19-2.56). Viral response was similar in patients with and without PDDIs (84.5% versus 86.4%; P=0.386). During follow-up, ART was modified in 134 patients with comedication regardless of the presence of PDDIs (P=0.524). CONCLUSIONS: PDDIs increase with complex ART and comorbidities. No adverse effect was noted on ART efficacy or tolerability; however, most PDDIs affected comedication but were manageable through dose adjustment or monitoring.|
|Keywords||*Anti-HIV Agents/administration & dosage — Central Nervous System Agents/administration & dosage — Cohort Studies — Comorbidity — *Drug Interactions — Drug Therapy, Combination — HIV Infections/complications/*drug therapy — HIV Protease Inhibitors/administration & dosage — Humans — Methadone/administration & dosage — *Polypharmacy — Prevalence — Reverse Transcriptase Inhibitors/administration & dosage — Switzerland|
This document has no fulltext available yet, but you can contact its author by using the form below.
|Research group||Unité HIV (46)|
|MARZOLINI, Catia et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. In: Antiviral Therapy, 2010, vol. 15, n° 3, p. 413-423. doi: 10.3851/IMP1540 https://archive-ouverte.unige.ch/unige:20513|